Evidence map›Paper›PMID 30867301›Full record

ArticleJournal of virology2019

Evolution of the HIV-1 Rev Response Element during Natural Infection Reveals Nucleotide Changes That Correlate with Altered Structure and Increased Activity over Time.

Chringma Sherpa, Patrick E H Jackson, Laurie R Gray, Kathryn Anastos, Stuart F J Le Grice, Marie-Louise Hammarskjold, David Rekosh

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Viral RNA structure analysis using DMS-MaPseq.Methods (San Diego, Calif.) · 2020
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chringma Sherpa *Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.
Patrick E H Jackson *Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Laurie R GrayMyles H. Thaler Center for HIV and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia, USA.
Kathryn AnastosAlbert Einstein College of Medicine and Montefiore Medical Center, Department of Medicine, Bronx, New York, USA.
Stuart F J Le GriceBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA legrices@mail.nih.gov dr4u@virginia.edu.
Marie-Louise HammarskjoldMyles H. Thaler Center for HIV and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia, USA.
David RekoshMyles H. Thaler Center for HIV and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia, USA legrices@mail.nih.gov dr4u@virginia.edu.ORCID 0000-0003-3662-4176
University of Virginia · USNational Institutes of Health · USAlbert Einstein College of Medicine · US

Funding

Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
HIV, HERV-K and Human CancerR01CA206275 · NCI · UNIVERSITY OF VIRGINIA · PI HAMMARSKJOLD, MARIE-LOUISE, REKOSH, DAVID M · 2017 to 2021
$2.2M
Compounds That Inhibit HIV Rev FunctionR01AI068501 · NIAID · UNIVERSITY OF VIRGINIA · PI REKOSH, DAVID M · 2006 to 2008
$1.3M
Functional Variation of Rev and RRE Activity During HIV InfectionR01GM110009 · NIGMS · UNIVERSITY OF VIRGINIA · PI HAMMARSKJOLD, MARIE-LOUISE, REKOSH, DAVID M · 2013 to 2016
$1.2M
Clinical Implications of HIV-1 Rev-Rev Response Element Functional Activity VariationK08AI136671 · NIAID · UNIVERSITY OF VIRGINIA · PI JACKSON, PATRICK EVAN HAGER · 2018 to 2022
$959k
Role of HIV Rev in Reactivation from LatencyR21AI134208 · NIAID · UNIVERSITY OF VIRGINIA · PI HAMMARSKJOLD, MARIE-LOUISE, REKOSH, DAVID M · 2017 to 2018
$443k
HIV Rev/RRE Variation and ConstraintsR21AI087505 · NIAID · UNIVERSITY OF VIRGINIA · PI REKOSH, DAVID M · 2010 to 2011
$417k
NCI NIH HHS R01 CA206275NIAID NIH HHS K08 AI136671NIAID NIH HHS R01 AI068501NIAID NIH HHS R21 AI087505NIAID NIH HHS R21 AI134208NIAID NIH HHS U01 AI035004NIGMS NIH HHS R01 GM110009
6 · The paper itself

Abstract

The HIV-1 Rev response element (RRE) is a

Indexed as

Gene Products, revGenes, envHIV-1HIV InfectionsHIV SeropositivityHumansMutationNucleic Acid ConformationNucleotidesProtein BindingResponse Elementsrev Gene Products, Human Immunodeficiency VirusRNA, MessengerRNA, ViralVirus ReplicationGene Products, revNucleotidesrev Gene Products, Human Immunodeficiency VirusRNA, MessengerRNA, ViralHIVHIV RevHIV RRERNA exportRNA structureviral sequence evolutionviral sequence variation

Identifiers

PMID30867301
PMCPMC6532081
OpenAlexW2945339933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.